Who will benefit from treatment against EGFR?

Lancet Oncol. 2005 May;6(5):257-8. doi: 10.1016/S1470-2045(05)70142-X.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics
  • ErbB Receptors / immunology
  • Female
  • Humans
  • Mutation
  • Receptor Protein-Tyrosine Kinases / immunology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • ErbB Receptors
  • Receptor Protein-Tyrosine Kinases